Tekturna's future looks dim as Novartis cuts 1,960 jobs
This article was originally published in Scrip
The future of Novartis's antihypertensive Tekturna/Rasilez (aliskiren) is looking increasingly bleak after the company announced today that it would accelerate planned sales force job cuts because of the recent failure of a major trial of the product. The Swiss firm is to cut its US field force by 1,630 positions and reduce staff at headquarters in New Jersey by 330 positions.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.